Related Experiment Video
Updated: Nov 23, 2025
Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
Published on: September 28, 2022
Epstein-Barr Virus and Multiple Sclerosis
Gunnar Houen1,2, Nicole Hartwig Trier2, Jette Lautrup Frederiksen2,3
1Institute of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark.
Abstract:
Multiple sclerosis (MS) is a neurologic disease affecting myelinated nerves in the central nervous system (CNS). The disease often debuts as a clinically isolated syndrome, e.g., optic neuritis (ON), which later develops into relapsing-remitting (RR) MS, with temporal attacks or primary progressive (PP) MS. Characteristic features of MS are inflammatory foci in the CNS and intrathecal synthesis of immunoglobulins (Igs), measured as an IgG index, oligoclonal bands (OCBs), or specific antibody indexes. Major predisposing factors for MS are certain tissue types (e.g., HLA DRB1*15:01), vitamin D deficiency, smoking, obesity, and infection with Epstein-Barr virus (EBV). Many of the clinical signs of MS described above can be explained by chronic/recurrent EBV infection and current models of EBV involvement suggest that RRMS may be caused by repeated entry of EBV-transformed B cells to the CNS in connection with attacks, while PPMS may be caused by more chronic activity of EBV-transformed B cells in the CNS. In line with the model of EBV's role in MS, new treatments based on monoclonal antibodies (MAbs) targeting B cells have shown good efficacy in clinical trials both for RRMS and PPMS, while MAbs inhibiting B cell mobilization and entry to the CNS have shown efficacy in RRMS. Thus, these agents, which are now first line therapy in many patients, may be hypothesized to function by counteracting a chronic EBV infection.
Insights
Multiple sclerosis (MS) is a neurologic condition linked to Epstein-Barr virus (EBV) infection. Treatments targeting B cells, potentially counteracting chronic EBV, show promise for both relapsing-remitting MS and primary progressive MS.
Area of Science:
- Neurology
- Immunology
- Virology
Background:
- Multiple sclerosis (MS) is a central nervous system (CNS) disease impacting myelinated nerves, often starting as optic neuritis (ON) and progressing to relapsing-remitting (RRMS) or primary progressive (PPMS) forms.
- Key MS characteristics include CNS inflammation and intrathecal immunoglobulin synthesis (IgG index, OCBs).
- Predisposing factors include HLA DRB1*15:01, vitamin D deficiency, smoking, obesity, and Epstein-Barr virus (EBV) infection.
Purpose of the Study:
- To explore the role of chronic Epstein-Barr virus (EBV) infection in the pathogenesis of multiple sclerosis (MS).
- To investigate the potential mechanisms by which EBV contributes to different MS subtypes (RRMS and PPMS).
- To evaluate the efficacy of B cell-targeting therapies in the context of EBV's role in MS.
Main Methods:
- Review of existing literature on MS pathogenesis, EBV infection, and B cell biology.
- Analysis of clinical trial data for monoclonal antibody (MAb) therapies in RRMS and PPMS.
- Correlation of clinical signs and disease progression with proposed EBV involvement models.
Main Results:
- Clinical signs of MS can be explained by chronic/recurrent EBV infection.
- Models suggest EBV-transformed B cells entering the CNS cause RRMS attacks, while chronic activity causes PPMS.
- B cell-targeting MAbs demonstrate efficacy in both RRMS and PPMS, supporting the EBV hypothesis.
Conclusions:
- Chronic EBV infection is a significant factor in MS development and progression.
- B cell-targeting therapies may counteract EBV's role in MS pathogenesis.
- Monoclonal antibodies targeting B cells represent a promising therapeutic strategy for MS, potentially by addressing underlying EBV activity.
More Related Videos
08:44Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
Published on: September 7, 2022
09:43An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
Published on: March 30, 2018